Selvita establishes UK subsidiary in Cambridge
The office is based in Cambridge, considered to be one of the most significant biotechnology clusters in the world. The new office will be responsible for supporting the
Johnson & Johnson (J&J) has agreed to purchase Firefly Bio for $1bn in cash, aiming to strengthen its oncology pipeline with Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) platform.
Under the deal, Cyclenium’s CMRT Technology-derived QUEST Library and associated hit-to-lead optimization expertise will be combined with Haplogen’s haploid genetics technology and expertise in host target identification, validation